Economic and Clinical Benefits of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV in Infants: A Cost-Effectiveness Analysis for Mexico

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in children. A novel RSVpreF vaccine for use among pregnant women for the prevention of RSV in infants is expected to be licensed in Mexico. Hence, the clinical and economic burden of RSV among infa...

ver descrição completa

Detalhes bibliográficos

Principais autores:	José Luis Huerta, Robyn Kendall, Luka Ivkovic, Carlos Molina, Amy W. Law, Diana Mendes
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2025-01-01
Colecção:	Vaccines
Assuntos:	cost-effectiveness respiratory syncytial virus (RSV) RSVpreF vaccine maternal immunization Mexico economic evaluation
Acesso em linha:	https://www.mdpi.com/2076-393X/13/1/77
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!